Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349934 | 0.90 | LCK (0.51) | NLRP3ATRSYKLCK | |
| SCHEMBL31167626 | 0.90 | LCK (0.51) | NLRP3ATRSYKLCK | |
| SCHEMBL29741502 | 0.89 | HDAC1 (0.51) | NLRP3ALDH1A1KMT2AATRSYK | |
| SCHEMBL23054108 | 0.89 | HTT (0.45) | NLRP3ALDH1A1KMT2AATRSYK | |
| SCHEMBL660566 | 0.89 | NLRP3 (0.43) | NLRP3ALDH1A1KMT2AATRSYK | |
| SCHEMBL4922310 | 0.88 | LMNA (0.43) | NLRP3ALDH1A1ATRSYKLCK | |
| SCHEMBL14908404 | 0.88 | KMT2A (0.49) | NLRP3ALDH1A1KMT2AATRSYK | |
| SCHEMBL1006953 | 0.88 | NLRP3 (0.43) | NLRP3ALDH1A1KMT2AATRSYK | |
| SCHEMBL29956316 | 0.88 | NLRP3 (0.43) | NLRP3ALDH1A1KMT2AATRSYK | |
| SCHEMBL1346055 | 0.88 | ALB (0.44) | NLRP3ALDH1A1KMT2AATRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118044519-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-110072842-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| US-8461345-B2 | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461345-B2 | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461345-B2 | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2562158-A1 | Processes for the preparation of n-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes | Vertex Pharmaceuticals Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2562158-A1 | Processes for the preparation of n-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes | Vertex Pharmaceuticals Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1603878-B1 | PROCESSES FOR THE PREPARATION OF N-HETEROARYL-N-ARYL-AMINES BY REACTING AN N-ARYL CARBAMIC ACID ESTER WITH A HALO-HETEROARYL AND ANALOGOUS PROCESSES | VERTEX PHARMA (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-1603878-B1 | PROCESSES FOR THE PREPARATION OF N-HETEROARYL-N-ARYL-AMINES BY REACTING AN N-ARYL CARBAMIC ACID ESTER WITH A HALO-HETEROARYL AND ANALOGOUS PROCESSES | VERTEX PHARMA (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316345-A1 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2010038428-A1 | ALTERNATIVE AGENT TO TAXANE ANTI-CANCER AGENT | 武田薬品工業株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| CN-100579965-C | Process for preparing N-heteroaryl-N-arylamines by reacting N-aryl carbamates with haloheteroaryls and analogous processes | VERTEX PHARMA CO LTD | 2010-01-13 | — | — | CN | disclosed |
| US-20070173649-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| US-20070173649-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| US-20070173649-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| US-7115746-B2 | Processes for the facile synthesis of diaryl amines and analogues thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-03 | — | — | US | disclosed |
| CN-1761653-A | Process for preparing N-heteroaryl-N-arylamines by reacting N-aryl carbamates with haloheteroaryls and analogous processes | VERTEX PHARMA (US) | 2006-04-19 | — | — | CN | disclosed |
| EP-1603878-A1 | PROCESSES FOR THE PREPARATION OF N-HETEROARYL-N-ARYL-AMINES BY REACTING AN N-ARYL CARBAMIC ACID ESTER WITH A HALO-HETEROARYL AND ANALOGOUS PROCESSES | Vertex Pharmaceuticals Incorporated (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040230058-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| WO-2004072038-A1 | PROCESSES FOR THE PREPARATION OF N-HETEROARYL-N-ARYL-AMINES BY REACTING AN N-ARYL CARBAMIC ACID ESTER WITH A HALO-HETEROARYL AND ANALOGOUS PROCESSES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230058-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | ABL1, PNMT, MAOA | NLRP3 2966/4885ALDH1A1 599/4885KMT2A 375/4885 |
| US-20070173649-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | ABL1, PNMT, MAOA | NLRP3 2966/4885ALDH1A1 599/4885KMT2A 375/4885 |
| US-20120316345-A1 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | MAPK1, NADK, NAMPT | NLRP3 1017/4885ALDH1A1 1275/4885KMT2A 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.